Somatostatin Analogs in Real‐World Practice for Patients with Metastatic Neuroendocrine Tumors: A Single Institution Experience in the Ouest of Algeria (CHU Oran) Abstract #3067

Introduction: The efficacy of somatostatin analogs (SSAs) were clearly established trough pivotal trials as first‐line agents for neuroendocrine tumors (NETs), but their use in clinical practice is largely unknown.
Aim(s): We aimed to understand real‐world management and treatment of gastroenteropancreatic (GEP) NETs.
Materials and methods: A retrospective analysis was performed for metastatic GEP‐NETs patients treated with SSAs at the medical oncology department of the academic hospital of Oran between January 1, 2011 and December 31, 2018. We reported descriptive statistics, clinical characteristics, treatment patterns, and healthcare resource use.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MD, PhD Nadia Ameziane

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2757 Effectiveness of Lanreotide 120 mg (LAN) in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumours (panNET) in Routine Clinical Practice
Introduction: PanNETs are the second most common type of tumour of the pancreas. Most patients have metastatic disease at diagnosis with median survival ranges from 2 to 5 years. Somatostatin analogs (SSAs) control symptoms and reduce tumour growth in panNET. In the panNET subgroup of the CLARINET study, lanreotide autogel 120 mg reduced the relative risk of progression or death by more than 40% compared with placebo at week 96.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: doctor Guillermo de La Cruz
#2884 An Infectious Diseases Specialist NET Patient Looks at Management of NETs
Introduction: Medical specialties may develop practices minimally influenced by other specialties.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Doctor George Schmid
Authors: Schmid G, ...
#2969 Lanreotide Autogel and Octreotide LAR Treatment Patterns: Results from a Nationwide French Retrospective Study
Introduction: Lanreotide autogel (LAN) and octreotide LAR (OCT) are long acting somatostatin analogues (LA-SSAs) used to treat acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Previous studies conducted in North America and Sweden showed some differences between both LA-SSAs in terms of dose and persistence.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Marion Feuilly
#3034 Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Is There Any Benefit When Ki-67 Is ≥ 10%?
Introduction: The antiproliferative effect of first-line long acting somatostatin analogs (SSA) in advanced gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) was shown in the PROMID and the CLARINET trials. Efficacy data in pancreatic NETs (PanNETs) with Ki-67 ≥ 10% are limited.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MD Teresa Alonso Gordoa
#3048 Somatostatin Analogs or Active Surveillance in Sporadic Non-Functioning Pancreatic Neuroendocrine Tumors
Introduction: Non-functioning (NF), sporadic pancreatic neuroendocrine tumors (pNETs) have usually an indolent behavior, but sometimes show an unpredictable aggressiveness. Surgery is the first-choice for localized tumors >2 cm. Unresectable or metastatic lesions expressing somatostatin receptors (SSTRs) are treated with Somatostatin analogs (SSAs). No evidence of SSAs efficacy exists in tumors ≤2 cm, for which active surveillance has been proposed.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: PhD Giovanni Schinzari